The earnings call reveals a decline in key financial metrics like gross margins, operating income, and EPS, with additional currency headwinds and increased expenses. Although management provides optimistic guidance for future recovery, the Q&A section indicates skepticism about margin improvements and the impact of the Fem Care sale. The strategic plan's focus on debt reduction and brand investments doesn't alleviate immediate financial pressures. Given the market cap of ~$2 billion, the negative sentiment is likely to result in a stock price decline of -2% to -8% over the next two weeks.